How much does Assimini’s medical insurance reimbursement cost?

Asciminib (Asciminib) is a third-generation tyrosine kinase inhibitor (TKI) used to treat chronic myelogenous leukemia (CML). It inhibits BCR-ABL "myristoyl" pocket of ABL1kinase. n>The activity of the fusion gene has shown significant efficacy, especially for patients who are resistant to first- and second-generation TKI drugs, especially those with the T315I mutation. Compared with traditional TKI drugs, Aceminib’s target is more precise, making it particularly effective in targeting specific patient groups in clinical practice.

Currently, Assimini is not yet on the market in China, so it cannot be purchased directly through domestic pharmacies or hospitals, and it has not yet been included in the domestic medical insurance directory. Therefore, patients in the country are still unable to purchase Asiminib through medical insurance reimbursement. If patients need to use the drug, they usually need to obtain it through overseas drug purchase channels.

Overseas, the original drug of Asiminib is mainly produced by European pharmaceutical companies, and the price is quite high. The price of each box is around tens of thousands of yuan, which puts great financial pressure on patients. For patients who cannot afford the high-priced original drugs, generic drugs in Laos have become an affordable option, with the price per box being about more than 4,000 yuan. The ingredients of generic drugs are basically the same as those of the original drugs, and they also perform well in terms of therapeutic effects, making them an important alternative for many patients.

Since Asiminib has not yet been launched in China, the problem of medical insurance reimbursement cannot be solved. Patients need to pay for the drug themselves, or reduce their financial burden through social donations, charity projects, etc. In the future, with the introduction of this drug in China, patients expect it to be included in the medical insurance list as soon as possible to provide more patients with affordable treatment options.